Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA )

4.360 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70
Open 4.360
Bid (Size) 4.350 (1)
Ask (Size) 4.950 (1)
Prev. Close 4.360
Today's Range 4.360 - 4.360
52wk Range 3.890 - 7.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
ZVRA stock results show that Zevra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value
Via Investor Brand Network

Performance

YTD
-36.16%
-36.16%
1 Month
-10.66%
-10.66%
3 Month
-14.76%
-14.76%
6 Month
-36.16%
-36.16%
1 Year
-14.17%
-14.17%

More News

Read More
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
From Kirby McInerney LLP
Via GlobeNewswire
Zevra Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Zevra Therapeutics
Via Benzinga
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 28, 2024
Via Benzinga
Zevra Therapeutics's Earnings: A Preview
Via Benzinga
Zevra Therapeutics's Earnings: A Preview
Via Benzinga
A Preview Of Zevra Therapeutics's Earnings
Via Benzinga
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director
Via Investor Brand Network
Topics Retirement
Exposures Pension
Earnings Scheduled For November 7, 2023
Via Benzinga
Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics
Via Benzinga
Why Is Acer Therapeutics Stock Trading Higher Today?
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
Via InvestorPlace
Earnings Scheduled For August 14, 2023
Via Benzinga
Earnings Scheduled For May 15, 2023
Via Benzinga
Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock?
Via Benzinga
Over $7M Bet On This Consumer Defensive Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.